Investors

2023

Ducat Ventures plc (AIM: DUC) announces that, at the General Meeting held earlier today, all resolutions were duly passed.

Accordingly the Share Consolidation, resulting in the Company's Existing Ordinary Share Capital being consolidated so that every 200 Existing Ordinary Shares are consolidated into 1 New Ordinary Share, will take place at 5pm on 4 August 2014. Following the Share Consolidation, but prior to the issuing of Consideration Shares or Placing Shares there will be 5,504,534 Ordinary Shares in issue.

In addition, the following proposals become unconditional in all respects upon Admission of the Enlarged Ordinary Share Capital to trading on AIM, for which application has been made and is expected to occur at 8am on 5 August 2014:

• the acquisition by the Company of the entire issued share capital of OpitBiotix Health Limited, resulting in the admission of 25,000,000 Consideration Shares and a change of business to become a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes
• the Placing, resulting in the admission of 41,250,000 Placing Shares

The Enlarged Ordinary Share Capital of the Company, comprising 71,754,534 New Ordinary Shares, will trade under the ISIN GB00BP0RTP38 and the TIDM of OPTI.

Following Admission, the Company's board will comprise:

• David Evans - Non-Executive Chairman
• Stephen O'Hara - Chief Executive Officer
• Adam Reynolds - Non-Executive Director
• Mark Wyatt - Non-Executive Director

The change of the Company's name to OptiBiotix Health Plc (AIM: OPTI), will become effective upon the registration of the Company's change of name at Companies House. A further announcement will be made in due course.

All of the defined terms in this announcement have the same meaning as in the circular published by the Company and sent to shareholders on 18 July 2014, a copy of which is available at:

http://www.rns-pdf.londonstockexchange.com/rns/6722M_-2014-7-17.pdf.

Total Voting Rights

For the purposes of the Disclosure and Transparency Rules, the total number of voting rights in the Company with effect from 5 August 2014 will be 71,754,534. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FCA's Disclosure and Transparency Rules.

Commenting, Adam Reynolds, Executive Chairman of Ducat, said:

"I am delighted that we have been able to conclude this transaction and I believe that we will create substantial shareholder value over the coming years."

For further information, please contact:

2022

Ducat Ventures plc (AIM: DUC) announces that, at the General Meeting held earlier today, all resolutions were duly passed.

Accordingly the Share Consolidation, resulting in the Company's Existing Ordinary Share Capital being consolidated so that every 200 Existing Ordinary Shares are consolidated into 1 New Ordinary Share, will take place at 5pm on 4 August 2014. Following the Share Consolidation, but prior to the issuing of Consideration Shares or Placing Shares there will be 5,504,534 Ordinary Shares in issue.

In addition, the following proposals become unconditional in all respects upon Admission of the Enlarged Ordinary Share Capital to trading on AIM, for which application has been made and is expected to occur at 8am on 5 August 2014:

• the acquisition by the Company of the entire issued share capital of OpitBiotix Health Limited, resulting in the admission of 25,000,000 Consideration Shares and a change of business to become a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes
• the Placing, resulting in the admission of 41,250,000 Placing Shares

The Enlarged Ordinary Share Capital of the Company, comprising 71,754,534 New Ordinary Shares, will trade under the ISIN GB00BP0RTP38 and the TIDM of OPTI.

Following Admission, the Company's board will comprise:

• David Evans - Non-Executive Chairman
• Stephen O'Hara - Chief Executive Officer
• Adam Reynolds - Non-Executive Director
• Mark Wyatt - Non-Executive Director

The change of the Company's name to OptiBiotix Health Plc (AIM: OPTI), will become effective upon the registration of the Company's change of name at Companies House. A further announcement will be made in due course.

All of the defined terms in this announcement have the same meaning as in the circular published by the Company and sent to shareholders on 18 July 2014, a copy of which is available at:

http://www.rns-pdf.londonstockexchange.com/rns/6722M_-2014-7-17.pdf.

Total Voting Rights

For the purposes of the Disclosure and Transparency Rules, the total number of voting rights in the Company with effect from 5 August 2014 will be 71,754,534. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FCA's Disclosure and Transparency Rules.

Commenting, Adam Reynolds, Executive Chairman of Ducat, said:

"I am delighted that we have been able to conclude this transaction and I believe that we will create substantial shareholder value over the coming years."

For further information, please contact:

2021

Ducat Ventures plc (AIM: DUC) announces that, at the General Meeting held earlier today, all resolutions were duly passed.

Accordingly the Share Consolidation, resulting in the Company's Existing Ordinary Share Capital being consolidated so that every 200 Existing Ordinary Shares are consolidated into 1 New Ordinary Share, will take place at 5pm on 4 August 2014. Following the Share Consolidation, but prior to the issuing of Consideration Shares or Placing Shares there will be 5,504,534 Ordinary Shares in issue.

In addition, the following proposals become unconditional in all respects upon Admission of the Enlarged Ordinary Share Capital to trading on AIM, for which application has been made and is expected to occur at 8am on 5 August 2014:

• the acquisition by the Company of the entire issued share capital of OpitBiotix Health Limited, resulting in the admission of 25,000,000 Consideration Shares and a change of business to become a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes
• the Placing, resulting in the admission of 41,250,000 Placing Shares

The Enlarged Ordinary Share Capital of the Company, comprising 71,754,534 New Ordinary Shares, will trade under the ISIN GB00BP0RTP38 and the TIDM of OPTI.

Following Admission, the Company's board will comprise:

• David Evans - Non-Executive Chairman
• Stephen O'Hara - Chief Executive Officer
• Adam Reynolds - Non-Executive Director
• Mark Wyatt - Non-Executive Director

The change of the Company's name to OptiBiotix Health Plc (AIM: OPTI), will become effective upon the registration of the Company's change of name at Companies House. A further announcement will be made in due course.

All of the defined terms in this announcement have the same meaning as in the circular published by the Company and sent to shareholders on 18 July 2014, a copy of which is available at:

http://www.rns-pdf.londonstockexchange.com/rns/6722M_-2014-7-17.pdf.

Total Voting Rights

For the purposes of the Disclosure and Transparency Rules, the total number of voting rights in the Company with effect from 5 August 2014 will be 71,754,534. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FCA's Disclosure and Transparency Rules.

Commenting, Adam Reynolds, Executive Chairman of Ducat, said:

"I am delighted that we have been able to conclude this transaction and I believe that we will create substantial shareholder value over the coming years."

For further information, please contact:

2020

Ducat Ventures plc (AIM: DUC) announces that, at the General Meeting held earlier today, all resolutions were duly passed.

Accordingly the Share Consolidation, resulting in the Company's Existing Ordinary Share Capital being consolidated so that every 200 Existing Ordinary Shares are consolidated into 1 New Ordinary Share, will take place at 5pm on 4 August 2014. Following the Share Consolidation, but prior to the issuing of Consideration Shares or Placing Shares there will be 5,504,534 Ordinary Shares in issue.

In addition, the following proposals become unconditional in all respects upon Admission of the Enlarged Ordinary Share Capital to trading on AIM, for which application has been made and is expected to occur at 8am on 5 August 2014:

• the acquisition by the Company of the entire issued share capital of OpitBiotix Health Limited, resulting in the admission of 25,000,000 Consideration Shares and a change of business to become a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes
• the Placing, resulting in the admission of 41,250,000 Placing Shares

The Enlarged Ordinary Share Capital of the Company, comprising 71,754,534 New Ordinary Shares, will trade under the ISIN GB00BP0RTP38 and the TIDM of OPTI.

Following Admission, the Company's board will comprise:

• David Evans - Non-Executive Chairman
• Stephen O'Hara - Chief Executive Officer
• Adam Reynolds - Non-Executive Director
• Mark Wyatt - Non-Executive Director

The change of the Company's name to OptiBiotix Health Plc (AIM: OPTI), will become effective upon the registration of the Company's change of name at Companies House. A further announcement will be made in due course.

All of the defined terms in this announcement have the same meaning as in the circular published by the Company and sent to shareholders on 18 July 2014, a copy of which is available at:

http://www.rns-pdf.londonstockexchange.com/rns/6722M_-2014-7-17.pdf.

Total Voting Rights

For the purposes of the Disclosure and Transparency Rules, the total number of voting rights in the Company with effect from 5 August 2014 will be 71,754,534. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FCA's Disclosure and Transparency Rules.

Commenting, Adam Reynolds, Executive Chairman of Ducat, said:

"I am delighted that we have been able to conclude this transaction and I believe that we will create substantial shareholder value over the coming years."

For further information, please contact:

2019

Ducat Ventures plc (AIM: DUC) announces that, at the General Meeting held earlier today, all resolutions were duly passed.

Accordingly the Share Consolidation, resulting in the Company's Existing Ordinary Share Capital being consolidated so that every 200 Existing Ordinary Shares are consolidated into 1 New Ordinary Share, will take place at 5pm on 4 August 2014. Following the Share Consolidation, but prior to the issuing of Consideration Shares or Placing Shares there will be 5,504,534 Ordinary Shares in issue.

In addition, the following proposals become unconditional in all respects upon Admission of the Enlarged Ordinary Share Capital to trading on AIM, for which application has been made and is expected to occur at 8am on 5 August 2014:

• the acquisition by the Company of the entire issued share capital of OpitBiotix Health Limited, resulting in the admission of 25,000,000 Consideration Shares and a change of business to become a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes
• the Placing, resulting in the admission of 41,250,000 Placing Shares

The Enlarged Ordinary Share Capital of the Company, comprising 71,754,534 New Ordinary Shares, will trade under the ISIN GB00BP0RTP38 and the TIDM of OPTI.

Following Admission, the Company's board will comprise:

• David Evans - Non-Executive Chairman
• Stephen O'Hara - Chief Executive Officer
• Adam Reynolds - Non-Executive Director
• Mark Wyatt - Non-Executive Director

The change of the Company's name to OptiBiotix Health Plc (AIM: OPTI), will become effective upon the registration of the Company's change of name at Companies House. A further announcement will be made in due course.

All of the defined terms in this announcement have the same meaning as in the circular published by the Company and sent to shareholders on 18 July 2014, a copy of which is available at:

http://www.rns-pdf.londonstockexchange.com/rns/6722M_-2014-7-17.pdf.

Total Voting Rights

For the purposes of the Disclosure and Transparency Rules, the total number of voting rights in the Company with effect from 5 August 2014 will be 71,754,534. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FCA's Disclosure and Transparency Rules.

Commenting, Adam Reynolds, Executive Chairman of Ducat, said:

"I am delighted that we have been able to conclude this transaction and I believe that we will create substantial shareholder value over the coming years."

For further information, please contact:

2018

Ducat Ventures plc (AIM: DUC) announces that, at the General Meeting held earlier today, all resolutions were duly passed.

Accordingly the Share Consolidation, resulting in the Company's Existing Ordinary Share Capital being consolidated so that every 200 Existing Ordinary Shares are consolidated into 1 New Ordinary Share, will take place at 5pm on 4 August 2014. Following the Share Consolidation, but prior to the issuing of Consideration Shares or Placing Shares there will be 5,504,534 Ordinary Shares in issue.

In addition, the following proposals become unconditional in all respects upon Admission of the Enlarged Ordinary Share Capital to trading on AIM, for which application has been made and is expected to occur at 8am on 5 August 2014:

• the acquisition by the Company of the entire issued share capital of OpitBiotix Health Limited, resulting in the admission of 25,000,000 Consideration Shares and a change of business to become a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes
• the Placing, resulting in the admission of 41,250,000 Placing Shares

The Enlarged Ordinary Share Capital of the Company, comprising 71,754,534 New Ordinary Shares, will trade under the ISIN GB00BP0RTP38 and the TIDM of OPTI.

Following Admission, the Company's board will comprise:

• David Evans - Non-Executive Chairman
• Stephen O'Hara - Chief Executive Officer
• Adam Reynolds - Non-Executive Director
• Mark Wyatt - Non-Executive Director

The change of the Company's name to OptiBiotix Health Plc (AIM: OPTI), will become effective upon the registration of the Company's change of name at Companies House. A further announcement will be made in due course.

All of the defined terms in this announcement have the same meaning as in the circular published by the Company and sent to shareholders on 18 July 2014, a copy of which is available at:

http://www.rns-pdf.londonstockexchange.com/rns/6722M_-2014-7-17.pdf.

Total Voting Rights

For the purposes of the Disclosure and Transparency Rules, the total number of voting rights in the Company with effect from 5 August 2014 will be 71,754,534. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FCA's Disclosure and Transparency Rules.

Commenting, Adam Reynolds, Executive Chairman of Ducat, said:

"I am delighted that we have been able to conclude this transaction and I believe that we will create substantial shareholder value over the coming years."

For further information, please contact: